Dublin, May 05, 2020 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Contract Manufacturing Market to 2027 - Global Analysis and Forecasts by Product; Service, and Geography" report has been added to ResearchAndMarkets.com's offering.
The biopharmaceuticals contract manufacturing market was valued at US$ 13,727.13 million in 2019 and is expected to grow at a CAGR of 8.2% from 2020 to 2027 to reach US$ 25,497.26 million by 2027.
Driving factors of the biopharmaceuticals contract manufacturing market are increasing trend of outsourcing among pharmaceuticals companies and elevating demand for biologics. However, growing competition in biopharmaceutical contract manufacturing industry is hindering the growth of the market.
The contract manufacturing organization (CMO) offers numerous benefits, including reducing investments in facilities and drug development costs, to pharmaceutical companies, thereby improving net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows pharmaceutical and biotechnology companies to redirect resources to other areas. A few years ago, the CMO industry was a niche service market, offering additional manufacturing capacity or specific services to pharmaceutical companies. Presently, many pharmaceuticals and biotechnology companies outsource various services from early-stage drug development to commercial-scale manufacturing. As the pharmaceuticals industry is shifting from large-scale production to more niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations is leading to the rise in inclination toward CMOs.
The global biopharmaceuticals contract manufacturing market is segmented into product and services. The biopharmaceuticals contract manufacturing market, by product, is segmented into biologics and biosimilars. The biologics segment held the largest share of the market in 2019, whereas the biosimilar segment is anticipated to register the highest CAGR in the market during the forecast period. Based on services, the market is segmented into development process, final dosage operations, and final packaging. The development process held the largest share of the market in 2019, whereas analytical and quality control segment is estimated to register the highest CAGR in the market during the forecast period.
Some of the essential primary and secondary sources included in the report are The Pharma & Biopharma Outsourcing Association (PBOA), Centers for Disease Control and Prevention, and Organization for Economic Co-operation and Development.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the biopharmaceuticals contract manufacturing market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global biopharmaceuticals contract manufacturing market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Key Topics Covered:
1. Introduction
2. Biopharmaceutical Contract Manufacturing Market - Key Takeaways
3. Research Methodology
4. Biopharmaceutical Contract Manufacturing - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinion
5. Biopharmaceuticals Contract Manufacturing Market - Industry Dynamics
5.1 Key Drivers
5.1.1 Increasing Outsourcing by Pharmaceutical Companies
5.1.2 Increasing Demand of Biologics
5.2 Key Market Restraints
5.2.1 Increasing Competition in the Industry
5.3 Key Market Opportunities
5.3.1 Emerging Markets
5.4 Future Trends
5.4.1 Consolidation in Pharmaceutical CMO Industry
5.5 Impact Analysis
6. Biopharmaceutical Contract Manufacturing Market - Global Analysis
6.1 Global Biopharmaceutical Contract Manufacturing Market Revenue Forecast And Analysis
6.2 Global Biopharmaceutical Contract Manufacturing Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
6.3.1 Lonza Group AG
6.3.2 Thermo Fisher Scientific, Inc.
7. Biopharmaceuticals Contract Manufacturing Market Analysis - By Product
7.1 Overview
7.2 Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2019 and 2027)
7.3 Biologics
7.3.1 Overview
7.3.2 Biologics: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.3.3 Monoclonal Antibodies
7.3.3.1 Overview
7.3.3.2 Monoclonal Antibodies: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.3.4 Recombinant Proteins
7.3.4.1 Overview
7.3.4.2 Recombinant Proteins: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.3.5 Vaccines
7.3.5.1 Overview
7.3.5.2 Vaccines: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.3.6 Others
7.3.6.1 Overview
7.3.7 Others: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Biosimilars
7.4.1 Overview
7.4.2 Biosimilars: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8. Biopharmaceuticals Contract Manufacturing Market - By Service
8.1 Overview
8.2 Biopharmaceuticals Contract Manufacturing Market, by Service, 2019 and 2027 (%)
8.3 Development Process
8.3.1 Overview
8.3.2 Development Process: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Final Dosage Operation
8.4.1 Overview
8.4.2 Final Dosage Operation: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Analytical and Quality Control
8.5.1 Overview
8.5.2 Analytical and Quality Control: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.6 Final Packaging
8.6.1 Overview
8.6.2 Final Packaging: Biopharmaceuticals Contract Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
9. Biopharmaceutical Contract Manufacturing Market - Geographic Analysis
9.1 North America: Biopharmaceutical Contract Manufacturing Market
9.2 Europe: Biopharmaceutical Contract Manufacturing Market
9.3 Asia Pacific: Biopharmaceutical Contract Manufacturing Market
9.4 Middle East & Africa: Biopharmaceutical Contract Manufacturing Market
9.5 South and Central America: Biopharmaceutical Contract Manufacturing Market
10. Impact of COVID-19 Pandemic on Biopharmaceutical Contract Manufacturing Market
10.1 North America: Impact assessment of COVID-19 Pandemic
10.2 Europe: Impact assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic
10.4 Rest of World: Impact Assessment of COVID-19 Pandemic
11. Biopharmaceutical Contract Manufacturing Market - Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 Boehringer Ingelheim International GmbH
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.2 THERMO FISHER SCIENTIFIC INC.
12.3 General Electric Company
12.4 MERCK KGAA
12.5 Lonza
12.6 Samsung Biologics.
12.7 AbbVie Inc.
12.8 WUXI BIOLOGICS
12.9 Ajinomoto Co. Inc.
12.10 Inno Bio Ventures Sdn Bhd
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
For more information about this report visit https://www.researchandmarkets.com/r/r4083n
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.